Agree relaxin. A major has to be in the action as a seller, and...

Agree relaxin.
A major has to be in the action as a seller, and possibly has been for some time.
As u have already stated, news releases are compounding towards further de-risked.
One plausible explanation is as follows.
With the new timeline (Ann), now delaying the extended arm in the AML and further cohort in the Ovarian trials towards end of 2019 due to chemo reducing techniques and the phase 2 breastcancer results not due till mid 2019, the question of a raise comes to mind.
Current funds (including tax rebate to come 2018), should suffice, yet no company wants to run funds that low..., Also need to allow for the clinical commencement of the ptx-100 due Q1/2 2019.
Regardless of the above financial hypotheticals, a great announcement for both breastcancer sufferers and PTX itself.